Physician profile
Michael Elist
NPI 1326340308
$335,896.51
in general payments reported to CMS, 2019-2025
23 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $35K · 2021: $24K · 2022: $40K · 2023: $34K · 2024: $33K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Food and Beverage: $9,980 · Travel and Lodging: $1,396 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,725.00 |
| Food and Beverage | $9,979.57 |
| Travel and Lodging | $1,395.54 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $217,334.68 | 2019-2025 | Otezla, Otezla, Evenity |
| Celgene Corporation | $63,399.81 | 2019 | |
| Abbvie INC. | $48,745.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,074.70 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,402.27 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $641.05 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $318.94 | 2019-2022 | |
| Kvk-Tech, INC. | $302.82 | 2019-2020 | |
| Pfizer INC. | $236.35 | 2019-2024 | |
| Janssen Biotech, INC. | $226.24 | 2019-2022 | |
| Ucb, INC. | $212.96 | 2025 | Bimzelx |
| Genentech USA, INC. | $206.04 | 2019 | |
| Dexcom, INC. | $191.77 | 2024-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $185.56 | 2021-2025 | Strensiq, Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $155.85 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $111.19 | 2021-2025 | Saphnelo |
| Kowa Pharmaceuticals America, INC. | $32.58 | 2022 | |
| Radius Health, INC. | $27.03 | 2023 | |
| Hologic Sales and Service, LLC | $19.90 | 2021 | |
| Mallinckrodt Hospital Products INC. | $19.82 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.45 | 2024 | Lupkynis |
| Janssen Scientific Affairs, LLC | $18.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Elist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.